新抗原標靶治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按目標疾病適應症、新抗原類型、免疫療法類型、給藥途徑、地區和競爭進行細分，2020-2030 年預測

2024 年全球新抗原標靶治療市場價值為 18.8 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 8.34%。新抗原標靶治療是癌症治療的一種尖端方法，利用免疫系統的力量來專門識別和攻擊癌細胞。這些療法旨在針對新抗原，新抗原是由於腫瘤 DNA 的突變而在癌細胞表面發現的獨特蛋白質片段。例如，根據《印度醫學研究雜誌》 2022 年 12 月發表的一項研究，預計 2022 年印度新增癌症病例數為 14,61,427 例。該報告強調了該國日益加重的癌症負擔，強調需要提高意識，早期發現，並改進治療策略，以應對不斷上升的發病率。新抗原不同於正常、健康的細胞蛋白，使其成為免疫辨識和攻擊的理想目標。新抗原治療是高度個人化的。一旦識別出新抗原，患者的免疫系統就會接受訓練，將這些特定的新抗原識別為外來入侵者。這通常涉及根據患者獨特的新抗原特徵創建客製化疫苗或過繼性細胞療法。新抗原療法可以與另一種免疫療法檢查點抑制劑合併使用。檢查點抑制劑釋放了免疫系統的煞車，使其能夠對癌細胞（包括新抗原所針對的癌細胞）產生更強的反應。

基因組定序技術的日益普及和經濟實惠使得人們能夠更準確、更快速地識別新抗原，從而促進個人化治療的發展。 FDA 和 EMA 等監管機構已表現出支持新抗原療法開發和批准的意願，簡化了這些治療方法的上市途徑。患者和醫療保健提供者擴大尋求專門針對癌細胞的精準治療方法。新抗原療法有望實現更有效、毒性更小的治療。研究人員正在探索將新抗原療法與其他治療方式（如化療和放射療法）結合的協同作用，以增強治療效果。人口老化使罹患癌症的風險更高。隨著全球人口老化，對包括新抗原療法在內的創新癌症治療的需求預計將上升。

主要市場促進因素

基因組檢測的進展

主要市場挑戰

相關新抗原的鑑定

主要市場趨勢

免疫療法占主導地位

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：COVID-19 對全球新抗原標靶治療市場的影響

第 5 章：顧客之聲

第6章：全球新抗原標靶治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依目標疾病適應症（骨癌、大腸直腸癌、婦科癌症、非小細胞肺癌、腎細胞癌）
  • 依新抗原類型（現成新抗原、個人化新抗原）
  • 依給藥途徑（皮內、靜脈、皮下）
  • 依免疫療法類型分類（樹突細胞疫苗、基於 DNA / RNA 的疫苗、基於蛋白質 / 肽的疫苗、基於 TIL 的療法）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 7 章：亞太地區新抗原標靶治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 8 章：歐洲新抗原標靶治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 9 章：北美新抗原標靶治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 10 章：南美洲新抗原標靶治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲新抗原標靶治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 12 章：市場動態

• 驅動程式
• 挑戰

第 13 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 14 章：全球新抗原標靶治療市場：SWOT 分析

第 15 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 16 章： 大環境分析

第 17 章：競爭格局

• BioNtech SE
• Gritstone Bio, Inc.
• Genocea Biosciences Inc
• Moderna Inc.
• Agenus Inc.
• Immatics NV
• Advaxis Inc.
• Precision Biologics
• Gilead Sciences, Inc.
• Cellular Biomedicine Group, Inc.
• Achillies Therapeutics Plc.
• Merck & Co, Inc.

第 18 章：策略建議

第19章調查會社について,免責事項

Global Neoantigen Targeted Therapies Market was valued at USD 1.88 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.34% through 2030. Neoantigen Targeted Therapies are a cutting-edge approach in cancer treatment that harnesses the power of the immune system to specifically recognize and attack cancer cells. These therapies are designed to target neoantigens, which are unique protein fragments found on the surface of cancer cells because of mutations in the tumor's DNA. For instance, according to a study published by the Indian Journal of Medical Research in December 2022, the estimated number of new cancer cases in India for 2022 was 14,61,427. The report highlights the growing cancer burden in the country, emphasizing the need for enhanced awareness, early detection, and improved treatment strategies to address the rising incidence. Neoantigens are distinct from normal, healthy cell proteins, making them ideal targets for immune recognition and attack. Neoantigen therapies are highly personalized. Once neoantigens are identified, the patient's immune system is trained to recognize these specific neoantigens as foreign invaders. This often involves creating a customized vaccine or adoptive cell therapy tailored to the patient's unique neoantigen profile. Neoantigen therapies can be used in combination with checkpoint inhibitors, another type of immunotherapy. Checkpoint inhibitors release the brakes on the immune system, allowing it to mount a stronger response against cancer cells, including those targeted by neoantigens.

The growing availability and affordability of genomic sequencing technologies have enabled the identification of neoantigens more accurately and quickly, facilitating the development of personalized therapies. Regulatory agencies like the FDA and EMA have shown willingness to support the development and approval of neoantigen therapies, streamlining the path to market for these treatments. Patients and healthcare providers are increasingly seeking precision therapies that specifically target cancer cells. Neoantigen therapies offer the potential for more effective and less toxic treatments. Researchers are exploring the synergistic effects of combining neoantigen therapies with other treatment modalities, such as chemotherapy and radiation therapy, to enhance treatment outcomes. The aging population is at higher risk of developing cancer. As the global population ages, the demand for innovative cancer treatments, including neoantigen therapies, is expected to rise.

Key Market Drivers

Advancements in Genomic Testing

Next-generation sequencing technologies have revolutionized the field of genomics. NGS allows for the rapid and cost-effective sequencing of large stretches of DNA. It has enabled the sequencing of entire genomes, transcriptomes, and epigenomes with unprecedented speed and affordability. For instance, a study published in PNAS in September 2022 reported that researchers developed an antibody-based therapy that successfully eliminated circulating tumor cells (CTCs) in breast cancer mouse models. This breakthrough highlights the potential of targeted immunotherapy in preventing cancer metastasis, offering hope for improved treatment strategies and better outcomes for breast cancer patients in the future. High-throughput sequencing platforms can simultaneously process numerous DNA or RNA samples, allowing for large-scale studies and population-scale genomic research. This capability has accelerated the discovery of genetic variants associated with diseases and traits. Traditional short-read sequencing methods have limitations in resolving complex genomic regions. Long-read sequencing technologies, like Pacific Biosciences (PacBio) and Oxford Nanopore, can generate much longer sequencing reads, aiding in the assembly of complete genomes and the identification of structural variations. Single-cell sequencing technologies enable the analysis of individual cells within a tissue or organism. This approach provides insights into cellular heterogeneity, cell types, and gene expression at a single-cell resolution, advancing our understanding of complex biological systems. Genomic sequencing has been instrumental in cancer research and precision oncology. It allows for the identification of driver mutations, assessment of tumor heterogeneity, and the development of targeted therapies tailored to a patient's genetic profile.

Key Market Challenges

Identification of Relevant Neoantigens

Tumors are often genetically heterogeneous, meaning they contain a mix of different cell types with various mutations. Identifying the specific neoantigens that are present across all tumor cells can be challenging. Neoantigen prediction relies on computational algorithms to predict potential neoantigens based on DNA sequencing data. These algorithms are continually improving, but false positives and false negatives are still common, leading to uncertainty in selecting the most relevant neoantigens. Predicted neoantigens must be experimentally validated to confirm their presentation on cancer cells and their immunogenicity. This validation process can be time-consuming and resource intensive. Each patient's tumor has a unique set of neoantigens, and these can vary greatly from one patient to another. Identifying relevant neoantigens requires a personalized approach for each patient, which can be logistically challenging. Some neoantigens may be present at very low frequencies within a tumor, making them difficult to detect and target effectively. Tumors can evolve over time, leading to changes in their neoantigen landscape. This requires ongoing monitoring and adaptation of neoantigen-targeted therapies. Cancer cells may develop mechanisms to evade the immune system, including downregulating the presentation of neoantigens. This immune evasion can hinder the effectiveness of neoantigen-targeted therapies.

Key Market Trends

Immunotherapy Dominance

Immunotherapy has gained prominence as a leading approach in cancer treatment. It harnesses the body's immune system to target and destroy cancer cells. Neoantigen-targeted therapies are a subset of immunotherapy that focuses on training the immune system to recognize and attack cancer-specific neoantigens. Immunotherapy, including neoantigen-targeted therapies, aligns with the principles of precision medicine. These therapies are tailored to the individual genetic and immunological profiles of each patient, aiming to maximize treatment efficacy while minimizing side effects. Neoantigen-targeted therapies often complement the use of checkpoint inhibitors, another class of immunotherapies. Checkpoint inhibitors release the brakes on the immune system, allowing it to attack cancer cells more effectively. Neoantigens can serve as specific targets for the immune system to recognize in combination with checkpoint inhibitors. Neoantigen-targeted therapies aim to enhance the immune system's response against cancer cells by targeting neoantigens, which are unique to the tumor. This can lead to a more focused and potent immune response compared to traditional treatments. Positive outcomes and clinical successes in immunotherapy trials, including neoantigen therapies, have fueled interest and investment in this field. Patients who have experienced durable responses are advocating for and raising awareness of these treatments. The pharmaceutical and biotechnology industries have invested heavily in the research and development of immunotherapies, including neoantigen-based approaches. This investment has led to a growing pipeline of potential therapies.

Key Market Players

• BioNtech SE
• Gritstone Bio, Inc.
• Genocea Biosciences Inc.
• Moderna Inc
• Agenus Inc.
• Immatics NV
• Advaxis Inc
• Precision Biologics
• Gilead Sciences, Inc.
• Cellular Biomedicine Group Inc.
• Achillies Therapeutics Plc.
• Merck & Co Inc

Report Scope:

In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neoantigen Targeted Therapies Market, By Target Disease Indication:

• Bone Cancer
• Colorectal Cancer
• Gynecological Cancer
• Non-Small Cell Lung Cancer
• Renal Cell Carcinoma

Neoantigen Targeted Therapies Market, By Neoantigens Type:

• Off-the-Shelf Neoantigens
• Personalized Neoantigens

Neoantigen Targeted Therapies Market, By Immunotherapy Type:

• Dendritic Cell Vaccines
• DNA / RNA-Based Vaccines
• Protein / Peptide-based Vaccines
• TIL-Based Therapies

Neoantigen Targeted Therapies Market, By Route of Administration:

• Intradermal
• Intravenous
• Subcutaneous

Neoantigen Targeted Therapies Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.

Available Customizations:

Global Neoantigen Targeted Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Neoantigen Targeted Therapies Market

5. Voice of Customer

6. Global Neoantigen Targeted Therapies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)
  • 6.2.2. By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)
  • 6.2.3. By Route of Administration (Intradermal, Intravenous, Subcutaneous)
  • 6.2.4. By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map

7. Asia Pacific Neoantigen Targeted Therapies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Target Disease Indication
  • 7.2.2. By Neoantigens Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Immunotherapy Type
  • 7.2.5. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Neoantigen Targeted Therapies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Target Disease Indication
      • 7.3.1.2.2. By Neoantigens Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Immunotherapy Type
  • 7.3.2. India Neoantigen Targeted Therapies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Target Disease Indication
      • 7.3.2.2.2. By Neoantigens Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Immunotherapy Type
  • 7.3.3. Australia Neoantigen Targeted Therapies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Target Disease Indication
      • 7.3.3.2.2. By Neoantigens Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Immunotherapy Type
  • 7.3.4. Japan Neoantigen Targeted Therapies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Target Disease Indication
      • 7.3.4.2.2. By Neoantigens Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Immunotherapy Type
  • 7.3.5. South Korea Neoantigen Targeted Therapies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Target Disease Indication
      • 7.3.5.2.2. By Neoantigens Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Immunotherapy Type

8. Europe Neoantigen Targeted Therapies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Target Disease Indication
  • 8.2.2. By Neoantigens Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Immunotherapy Type
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Neoantigen Targeted Therapies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Target Disease Indication
      • 8.3.1.2.2. By Neoantigens Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Immunotherapy Type
  • 8.3.2. Germany Neoantigen Targeted Therapies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Target Disease Indication
      • 8.3.2.2.2. By Neoantigens Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Immunotherapy Type
  • 8.3.3. Spain Neoantigen Targeted Therapies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Target Disease Indication
      • 8.3.3.2.2. By Neoantigens Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Immunotherapy Type
  • 8.3.4. Italy Neoantigen Targeted Therapies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Target Disease Indication
      • 8.3.4.2.2. By Neoantigens Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Immunotherapy Type
  • 8.3.5. United Kingdom Neoantigen Targeted Therapies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Target Disease Indication
      • 8.3.5.2.2. By Neoantigens Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Immunotherapy Type

9. North America Neoantigen Targeted Therapies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Target Disease Indication
  • 9.2.2. By Neoantigens Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Immunotherapy Type
  • 9.2.5. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Neoantigen Targeted Therapies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Target Disease Indication
      • 9.3.1.2.2. By Neoantigens Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Immunotherapy Type
  • 9.3.2. Mexico Neoantigen Targeted Therapies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Target Disease Indication
      • 9.3.2.2.2. By Neoantigens Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Immunotherapy Type
  • 9.3.3. Canada Neoantigen Targeted Therapies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Target Disease Indication
      • 9.3.3.2.2. By Neoantigens Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Immunotherapy Type

10. South America Neoantigen Targeted Therapies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Target Disease Indication
  • 10.2.2. By Neoantigens Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Immunotherapy Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neoantigen Targeted Therapies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Target Disease Indication
      • 10.3.1.2.2. By Neoantigens Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Immunotherapy Type
  • 10.3.2. Argentina Neoantigen Targeted Therapies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Target Disease Indication
      • 10.3.2.2.2. By Neoantigens Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Immunotherapy Type
  • 10.3.3. Colombia Neoantigen Targeted Therapies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Target Disease Indication
      • 10.3.3.2.2. By Neoantigens Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Immunotherapy Type

11. Middle East and Africa Neoantigen Targeted Therapies Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Target Disease Indication
  • 11.2.2. By Neoantigens Type
  • 11.2.3. By Route of Administration
  • 11.2.4. By Immunotherapy Type
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Neoantigen Targeted Therapies Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Target Disease Indication
      • 11.3.1.2.2. By Neoantigens Type
      • 11.3.1.2.3. By Route of Administration
      • 11.3.1.2.4. By Immunotherapy Type
  • 11.3.2. Saudi Arabia Neoantigen Targeted Therapies Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Target Disease Indication
      • 11.3.2.2.2. By Neoantigens Type
      • 11.3.2.2.3. By Route of Administration
      • 11.3.2.2.4. By Immunotherapy Type
  • 11.3.3. UAE Neoantigen Targeted Therapies Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Target Disease Indication
      • 11.3.3.2.2. By Neoantigens Type
      • 11.3.3.2.3. By Route of Administration
      • 11.3.3.2.4. By Immunotherapy Type

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Neoantigen Targeted Therapies Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. BioNtech SE
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (In case of listed companies)
  • 17.1.5. Recent Developments
• 17.2. Gritstone Bio, Inc.
• 17.3. Genocea Biosciences Inc
• 17.4. Moderna Inc.
• 17.5. Agenus Inc.
• 17.6. Immatics N.V.
• 17.7. Advaxis Inc.
• 17.8. Precision Biologics
• 17.9. Gilead Sciences, Inc.
• 17.10. Cellular Biomedicine Group, Inc.
• 17.11. Achillies Therapeutics Plc.
• 17.12. Merck & Co, Inc.

18. Strategic Recommendations

19. About Us & Disclaimer